Low-grade Glioma Clinical Trials in Washington D.C., District of Columbia
5 recruitingWashington D.C., District of Columbia
Showing 1–5 of 5 trials
Recruiting
Phase 3
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Low-grade GliomaLow Grade AstrocytomaWHO Grade 2 Glioma+3 more
National Cancer Institute (NCI)170 enrolled132 locationsNCT04166409
Recruiting
Phase 1
Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
High Grade GliomaLow-grade GliomaRecurrent World Health Organization (WHO) Grade II Glioma
University of California, San Francisco50 enrolled17 locationsNCT04485559
Recruiting
Phase 3
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
Low-grade GliomaRapidly Accelerated Fibrosarcoma (RAF) Altered GliomaPediatric Low-grade Glioma
Day One Biopharmaceuticals, Inc.400 enrolled138 locationsNCT05566795
Recruiting
Phase 1Phase 2
MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
High Grade GliomaLow-grade Glioma
Ann & Robert H Lurie Children's Hospital of Chicago27 enrolled3 locationsNCT06712875
Recruiting
Phase 2
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
Advanced Solid TumorLow-grade Glioma
Day One Biopharmaceuticals, Inc.141 enrolled35 locationsNCT04775485